Biocon Pharma receives approval for ANDA from USFDA

Biocon Pharma Limited, a subsidiary of Biocon Limited, received approval of its ANDA for Posaconazole Delayed-Release tablets from the US FDA. This product is indicated for use in the prevention of certain fungal infections in patients with severely weakened immune systems and is available in 100mg strength. This approval further adds to Biocon's portfolio of vertically integrated complex drug products.

Shares of Biocon Limited was last trading in BSE at Rs. 399.95 as compared to the previous close of Rs. 391.55. The total number of shares traded during the day was 284799 in over 5477 trades.

The stock hit an intraday high of Rs. 404.50 and intraday low of 391.00. The net turnover during the day was Rs. 113668905.00.

Source : Equity Bulls

Keywords

Biocon INE376G01013 BioconPharma ANDAApproval USFDA Posaconazole FungalInfection